Narrative review: blood and tumor biomarker testing in non-small cell lung cancer without an oncogenic driver.

ABSTRACT:

Background and objective

For patients with metastatic non-small cell lung cancer (NSCLC) without an oncogenic driver, systemic therapy with immune checkpoint inhibitors (ICIs) alone or in combination with chemotherapy have significantly improved the outcomes. However, the majority of patients do not have a durable response, and there is a need for additional predictive biomarkers. The objective of this narrative review is to describe potential biomarkers for immunotherapy.

Methods

Narrative overview of the literature synthesizing the findings of literature reporting retrospective, prospective, and subset analyses of studies investigating potential predictive biomarkers for ICI.

Key content and findings

Tumor expression of programmed death ligand-1 (PD-L1) is the only

SUBMITTER: Stinchcombe TE 

PROVIDER: S-EPMC9903081 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature